Research programme: peptide-based viral vaccines - Renaptys

Drug Profile

Research programme: peptide-based viral vaccines - Renaptys

Alternative Names: Candidate 5P - Renaptys; REN-1005P

Latest Information Update: 01 Oct 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Renaptys Vaccines
  • Class Antigens; Influenza virus vaccines; Peptide vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Influenza virus infections
  • Research Respiratory syncytial virus infections; Rotavirus infections

Most Recent Events

  • 22 Sep 2013 Early research in Respiratory syncytial virus infections in USA (Parenteral)
  • 22 Sep 2013 Early research in Rotavirus infections in USA (Parenteral)
  • 22 Sep 2013 Preclinical trials in Influenza virus infections (prevention; seasonal and pandemic strains) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top